TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma

References

• Altekruse SF, Mcglynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491. doi:10.1200/JCO.2008.20.7753.
   PubMed Web of Science ®Google Scholar
• Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular expression of SIRT1 and its effect on hepatocellular carcinoma progression: a future therapeutic perspective. Int J Hepatol. 2020;2020:1–10. doi:10.1155/2020/2374615.
   Web of Science ®Google Scholar
• Benowitz S. Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst. 2007;99:590–591. doi:10.1093/jnci/djk174.
   PubMedGoogle Scholar
• Zvereva M, Roberti G, Durand G, Voegele C, Calvez-Kelm FL, Delhomme TM, Chopard P, Fabianova E, Adamcakova Z, Holcatova I. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA. EBioMedicine. 2020:102462. doi:10.1016/j.ebiom.2019.09.042
   PubMed Web of Science ®Google Scholar
• Lee J, Ji HK, Sun HK, Yoo HM. 2020. Improvement of digital PCR conditions for direct detection of KRAS mutations. J Clin Lab Anal. 34. DOI:10.1002/jcla.23344
   Web of Science ®Google Scholar
• Schwarzenbach H, Hoon D, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer Clin Oncol. 2011;1:426.
   Google Scholar
• Jahr S, Hentze H, Englisch S, Hardt D, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665.
   PubMed Web of Science ®Google Scholar
• Sharma A, Johnson A, Chen S, Li Y, Hu H, Cai Y, Hou L. Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J Cell Physiol. 2020:235. doi:10.1002/jcp.29837
   PubMed Web of Science ®Google Scholar
• Allenson K, Castillo J, Lucas FS, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017;28:741–747. doi:10.1093/annonc/mdx004.
   PubMed Web of Science ®Google Scholar
• Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467–472. doi:10.1038/nature25432.
   PubMed Web of Science ®Google Scholar
• Yang S, Che S, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biology & Therapy. 2017;18(3):158–165. doi:10.1080/15384047.2017.1281499.
   PubMed Web of Science ®Google Scholar
• Bernard V, Dong UK, Lucas F, Castillo J, Alvarez HA, Mulu Feven C, Stephens Bret M, Huang Jonathan, Semaan Alexander, Guerrero Paola A, Kamyabi Nabiollah, Zhao Jun, Hurd Mark W, Koay Eugene J, Taniguchi Cullen M, Herman Joseph M, Javle Milind, Wolff Robert, Katz Matthew, Varadhachary Gauri, Maitra Anirban et al. Circulating nucleic acids associate with outcomes of patients with pancreatic cancer. Gastroenterology. 2018;156(1):108–118.e4.
   Web of Science ®Google Scholar
• Liu Y, Wang Y, Lv Q, Li X. Exosomes: from garbage bins to translational medicine. Int J Pharm. 2020;583:119333. doi:10.1016/j.ijpharm.2020.119333.
   PubMedGoogle Scholar
• Jin Y, Chen K, Wang Z, Wang Y, Liu J, Lin L, Shao Y, Gao L, Yin H, Cui C, et al. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016;16(1):753. doi:10.1186/s12885-016-2783-2.
   PubMed Web of Science ®Google Scholar
• Qu X, Li Q, Yang J, Zhao H, Xiao W, Zhang F, Zhang S, Zhang H, Wang R, Wang Q. Double-stranded DNA in exosomes of malignant pleural effusions as a novel DNA source for EGFR mutation detection in lung adenocarcinoma. Front Oncol. 2019;9:931. doi:10.3389/fonc.2019.00931.
   PubMed Web of Science ®Google Scholar
• Liao W, Yang H, Xu H, Wang Y, Ge P, Ren J, Xu W, Lu X, Sang X, Zhong S. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016;7(26):40481–40490. doi:10.18632/oncotarget.9629.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang A, Wang YP, Yin Y, Zhou J, Zhang X, Zhou J. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma. Ann Transl Med. 2020;8:237. doi:10.21037/atm.2019.12.154.
   PubMed Web of Science ®Google Scholar
• Shen T, Li SF, Wang JL, Zhang T, Zhang S, Chen H-T, Xiao Q-Y, Ren W-H, Liu C, Peng B, et al. TP53 R249S mutation detected in circulating tumour DNA is associated with prognosis of hepatocellular carcinoma patients with or without hepatectomy. Liver Int. 2020;40:2834–2847. doi:10.1111/liv.14581.
   PubMed Web of Science ®Google Scholar
• Chennakrishnaiah S, Meehan B, D’Asti E, Montermini L, Rak J, Karatzas N, Buchanan M, Tawil N, Choi D, Divangahi M. Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumorヾerived extracellular vesicles. J Thrombosis Haemostasis. 2018;16(9):1800–1813. doi:10.1111/jth.14222.
   PubMed Web of Science ®Google Scholar
• Wang L, Li Y, Guan X, Zhao J, Shen L, Liu J. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma. Mol Cancer. 2018;17(1):128. doi:10.1186/s12943-018-0876-z.
   PubMedGoogle Scholar
• Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182. doi:10.1038/nature14581.
   PubMed Web of Science ®Google Scholar
• Lino M, Huang, Helen HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, et al. Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers. Clin Cancer Res. 2017;24(1):181–188. doi:10.1158/1078-0432.CCR-17-2007.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. doi:10.1038/nm.1789.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586. doi:10.1200/JCO.2012.45.2011.
   PubMed Web of Science ®Google Scholar
• Liao W, Mao Y, Ge P, Yang H, Xu H, Lu X, Sang X, Zhong S. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine. 2015;94(14):e722. doi:10.1097/MD.0000000000000722.
   PubMed Web of Science ®Google Scholar
• Huggett JF, Foy CA, Benes V, Emslie K, Garson Jeremy A, Haynes Ross, Hellemans Jan, Kubista Mikael, Mueller Reinhold D, Nolan Tania, Pfaffl Michael W, Shipley Gregory L, Vandesompele Jo, Wittwer Carl T, Bustin Stephen A et al. The digital miqe guidelines: minimum information for publication of quantitative digital PCR experiments. Clin Chem. 2013;59(6):892–902.
   Web of Science ®Google Scholar
• Wang ZY, Wang RX, Ding XQ, Zhang X, Tong JH. A protocol for cancer-related mutation detection on exosomal DNA in clinical application. Front Oncol. 2020;10:558106. doi:10.3389/fonc.2020.558106.
   PubMed Web of Science ®Google Scholar